Recursion Pharmaceuticals, Inc.
RXRX
$3.05
-$0.10-3.18%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -56.11% | 681.74% | -80.16% | 33.34% | 6.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -56.11% | 681.74% | -80.16% | 33.34% | 6.89% |
| Cost of Revenue | -33.72% | -0.82% | 56.61% | 79.00% | 92.39% |
| Gross Profit | 31.31% | 29.93% | -115.48% | -88.58% | -110.56% |
| SG&A Expenses | -36.70% | -45.36% | 10.25% | 46.56% | 74.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.51% | -19.08% | 42.54% | 70.02% | 87.15% |
| Operating Income | 32.85% | 36.41% | -75.08% | -75.28% | -98.64% |
| Income Before Tax | 39.74% | 39.57% | -69.58% | -75.29% | -119.90% |
| Income Tax Expenses | -2,813.92% | 185.71% | -98.20% | -- | 79.72% |
| Earnings from Continuing Operations | 41.97% | 39.56% | -69.29% | -76.23% | -121.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.97% | 39.56% | -69.29% | -76.23% | -121.60% |
| EBIT | 32.85% | 36.41% | -75.08% | -75.28% | -98.64% |
| EBITDA | 36.74% | 43.00% | -65.82% | -66.40% | -93.38% |
| EPS Basic | 55.84% | 61.44% | -7.02% | -2.28% | -29.86% |
| Normalized Basic EPS | 54.15% | 58.40% | -7.23% | -1.70% | -28.89% |
| EPS Diluted | 55.84% | 61.44% | -7.02% | -2.28% | -29.86% |
| Normalized Diluted EPS | 54.15% | 58.40% | -7.23% | -1.70% | -28.89% |
| Average Basic Shares Outstanding | 31.42% | 56.75% | 58.18% | 72.32% | 70.65% |
| Average Diluted Shares Outstanding | 31.42% | 56.75% | 58.18% | 72.32% | 70.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |